Children should receive the first dose of the human papillomavirus vaccine at age 11 to 12, although vaccination can be initiated as early as age 9. This timing is the routine recommendation of the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention and is supported by the Strategic Advisory Group of Experts on Immunization, World Health Organization and the Committee on Infectious Diseases, American Academy of Pediatrics. Early adolescent vaccination produces a stronger immune response and protects individuals before they are exposed to HPV through sexual contact.
Recommended schedule and special cases
For most children who begin the series before their 15th birthday, two doses are given, with the second dose administered 6 to 12 months after the first, according to the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. If the series is started at age 15 or older, or if a child has significant immunocompromise, a three-dose schedule is recommended. Catch-up vaccination is advised for those who did not complete the series on schedule; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention guidance notes routine catch-up through age 26 and individualized decision-making for adults aged 27 to 45.
Why early vaccination matters
HPV is a common sexually transmitted infection that can cause cervical, anal, penile and oropharyngeal cancers. The vaccine is preventive, not therapeutic, and is most effective when given before exposure to the virus. International and national public health bodies, including the Strategic Advisory Group of Experts on Immunization, World Health Organization, cite reductions in HPV infection rates and precancerous cervical lesions in populations with high vaccination coverage. Safety surveillance conducted by the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention and reviewed by World Health Organization panels shows the vaccine’s safety profile has been consistently favorable.
Practical, cultural and territorial nuances
Global uptake varies by country and region. The World Health Organization recommends HPV vaccine inclusion in national immunization schedules where feasible, and Gavi, the Vaccine Alliance supports introduction and access in low-income countries. Cultural beliefs about adolescent sexuality, health system capacity, and vaccine access shape real-world coverage; in some settings, parental concern about sexual behaviour or misinformation reduces uptake, while strong school-based programs and public health campaigns increase it. Health professionals, guided by the Committee on Infectious Diseases, American Academy of Pediatrics, are advised to present the vaccine as cancer prevention to reduce stigma and improve acceptance.
Timely vaccination yields both individual protection and population-level benefits through herd effects, lowering HPV circulation and downstream cancer risk. Families should consult their pediatrician or local public health authority for specific scheduling, vaccine options, and local program details aligned with Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention and World Health Organization guidance.